Medical Device Collaboration and Licensing Deals 2016-2025: Comprehensive Listing of 903 Deals Including Financial Terms - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Medical Device Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.

This report contains a comprehensive listing of 903 medical device deals announced since 2016 including financial terms where available, and links to online deal records of actual medical device partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Medical Device Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the medical device deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of medical device deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter medical device deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

The initial chapters of this report offer an orientation of medical device dealmaking, starting with an introduction, followed by an overview of dealmaking trends since 2016. Subsequent chapters delve into leading medical device deals, count the top 25 most active companies, and provide detailed reviews of signed deals. They are organized by company activity and by technology type.

The report also includes numerous tables and figures that illustrate the trends and activities in medical device dealmaking since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Medical Device Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse medical device collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report Scope

Medical Device Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of medical device trends and structure of deals entered into by leading biopharma companies worldwide.

Medical Device Collaboration and Licensing Deals includes:

• Trends in medical device dealmaking in the biopharma industry
• Directory of medical device deal records covering pharmaceutical and biotechnology
• The leading medical device deals by value
• Most active medical device licensing dealmakers

Medical Device Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Companies Featured

• 3M
• AbbVie
• Accenture
• Adobe Systems
• Akamai Technologies
• Alibaba Group
• Allianz
• Alphabet Inc.
• Amazon
• American Express
• Apple
• AT&T Inc.
• Bank of America
• Bayer AG
• BioNTech
• Boehringer Ingelheim
• Boeing
• BP plc
• Broadcom
• Cisco Systems
• Comcast
• Costco Wholesale
• Daimler AG
• Eli Lilly
• ExxonMobil
• Facebook
• General Electric
• GlaxoSmithKline
• Goldman Sachs
• Hewlett-Packard
• IBM
• Intel
• Johnson & Johnson
• JPMorgan Chase
• Kraft Heinz
• Lockheed Martin
• MasterCard
• McDonald's
• Merck & Co.
• Microsoft
• Nestle
• Nike
• Pfizer
• Procter & Gamble
• Qualcomm
• Roche
• SAP SE
• Shell
• Tesla, Inc.
• Verizon Communications
• Visa Inc.

For more information about this report visit https://www.researchandmarkets.com/r/z35wf

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.